Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant

Vascular factors, angiogenesis and biliary tract disease

(2010) Shannon S Glaser et al.   CURRENT OPINION IN GASTROENTEROLOGY

Drug therapy: Sorafenib

(2010) Richard S. Finn   HEPATOLOGY

Sorafenib for Recurrent Hepatocellular Carcinoma After Liver Transplantation

(2010) D. H. Yoon et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Safety and Feasibility of Using Sorafenib in Recurrent Hepatocellular Carcinoma after Orthotopic Liver Transplantation

(2010) Richard Kim et al.   ONCOLOGY

Treating Hepatocellular Carcinoma With Sorafenib in Liver Transplant Patients: An Initial Experience

(2010) R.F. Saidi et al.   TRANSPLANTATION PROCEEDINGS

Sorafenib

(2009) Gillian M. Keating et al.   DRUGS

Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety

(2009) Alessandro Vitale et al.   HEPATOLOGY

Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2

(2009) Boris R. A. Blechacz et al.   HEPATOLOGY

Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib®versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation – HeiLivCa [ISRCTN24081794]

(2008) K Hoffmann et al.   BMC CANCER

Novel advancements in the management of hepatocellular carcinoma in 2008

(2008) Josep M. Llovet et al.   JOURNAL OF HEPATOLOGY

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE